Multidisciplinary Treatment of Primary Melanoma

作者：Yao Katharine^*; Balch Glen; Winchester David J

来源：Surgical Clinics of North America, 2009, 89(1): 267-+.

DOI：10.1016/j.suc.2008.11.002

• Melanoma
• Sentinel node
• Immunotherapy
• Interferon
• Melanoma vaccine
• Thin melanomas
• Breslow thickness

This article covers the multidisciplinary treatment of primary melanoma. Excision margins and the need for sentinel lymphadenectomy are mainly dictated by the Breslow thickness although exceptions to this dictum do exist. Interferon is the only FDA approved adjuvant therapy for high risk melanoma although its overall survival benefit is minimal. Trials examining different doses or duration of interferon therapy have not demonstrated any promising survival data so far. There have been several randomized vaccine trials for melanoma but none have shown an overall survival benefit. Research into T-cell regulation continues and will hopefully bring promise for the future of melanoma treatment.

• 出版日期2009-2
• 单位西北大学